Yu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu Zhang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Guohua Mao
Tianjin Medical University Cancer Institute and Hospital Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer Tianjin, PR China
8 shared publications - Jihui Hao
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, China
8 shared publications - Jingbo Xu
Tianjin Medical University Cancer Institute and Hospital Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer Tianjin, PR China
8 shared publications - Jingrui Yan
Tianjin Medical University Cancer Institute and Hospital Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer Tianjin, PR China
8 shared publications - Shangheng Shi
Tianjin Medical University Cancer Institute and Hospital Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer Tianjin, PR China
8 shared publications - Tianxing Zhou
Pancreas Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
8 shared publications
Latest Publications
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF18
Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps
Chemotherapy remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet it paradoxically promotes metastatic recurrence. Elucidation of the underlying mechanisms mediating chemotherapy-induced metastasis could help identify improved combination treatment strategies. In this study, we used a dormancy-tracking system to show that chemotherapy awakens dormant disseminated tumor cells (DTC) in the liver by inducing hepatocyte senescence and subsequent neutrophil extracellular trap (NET) formation. In human and mouse cohorts, adjuvant and neoadjuvant chemotherapy triggered hepatocyte senescence, leading to TGFβ secretion and SMAD-dependent NETosis. NET-derived DNA engaged the transmembrane receptor CCDC25 on dormant DTCs, activating PI3K–AKT signaling and reprogramming DTCs toward a lipid-laden, proliferative phenotype. Genetic or pharmacologic disruption of NET formation, TGFβ signaling, or CCDC25 function effectively suppressed DTC reactivation and hepatic metastasis without compromising chemotherapy efficacy. Clinically, elevated serum NET-DNA levels correlated with hepatocyte senescence, DTC proliferation, and poor survival in PDAC and other solid tumors. Taken together, these findings unveil a senescence–NET–CCDC25 axis that links chemotherapy-induced tissue damage to metastatic relapse, providing a mechanistic basis for adjuvant and neoadjuvant strategies targeting NETosis and CCDC25 to prevent recurrence in PDAC. Significance: Chemotherapy induces hepatocyte senescence and neutrophil extracellular trap formation that activates CCDC25 signaling to awaken dormant disseminated pancreatic cancer cells in the liver, providing mechanistic insights and therapeutic opportunities for preventing relapse.
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF18
Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps
Chemotherapy remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet it paradoxically promotes metastatic recurrence. Elucidation of the underlying mechanisms mediating chemotherapy-induced metastasis could help identify improved combination treatment strategies. In this study, we used a dormancy-tracking system to show that chemotherapy awakens dormant disseminated tumor cells (DTC) in the liver by inducing hepatocyte senescence and subsequent neutrophil extracellular trap (NET) formation. In human and mouse cohorts, adjuvant and neoadjuvant chemotherapy triggered hepatocyte senescence, leading to TGFβ secretion and SMAD-dependent NETosis. NET-derived DNA engaged the transmembrane receptor CCDC25 on dormant DTCs, activating PI3K–AKT signaling and reprogramming DTCs toward a lipid-laden, proliferative phenotype. Genetic or pharmacologic disruption of NET formation, TGFβ signaling, or CCDC25 function effectively suppressed DTC reactivation and hepatic metastasis without compromising chemotherapy efficacy. Clinically, elevated serum NET-DNA levels correlated with hepatocyte senescence, DTC proliferation, and poor survival in PDAC and other solid tumors. Taken together, these findings unveil a senescence–NET–CCDC25 axis that links chemotherapy-induced tissue damage to metastatic relapse, providing a mechanistic basis for adjuvant and neoadjuvant strategies targeting NETosis and CCDC25 to prevent recurrence in PDAC. Significance: Chemotherapy induces hepatocyte senescence and neutrophil extracellular trap formation that activates CCDC25 signaling to awaken dormant disseminated pancreatic cancer cells in the liver, providing mechanistic insights and therapeutic opportunities for preventing relapse.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure1-24 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Fig.S1. Analysis of the number of positive LNs and the lymph node ratio (LNR, the ratio of positive to examined nodes) in PDAC patients; Fig.S2. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S3. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S4. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S5. Validation of SPiDER probe and the effects of dasatinib plus quercetin; Fig.S6. The gating strategy for senescent cells and the senescence levels in normal tissues, IPMN and PDAC; Fig.S7. The effects of specific deletion of p16 and p21 in CAFs; Fig.S8.The effects of conditional deletion of p16 and p21 in CAFs; Fig.S9. Clinical significance of senescent CAFs in PDAC; Fig.S10. The paracrine effects of malignant epithelial components on the induction of senescent CAFs; Fig.S11. The validation of senescent CAFs; Fig.S12. The glucose metabolism level in senescent CAFs; Fig.S13. The effects of LDHA inhibition in LNM; Fig.S14. The effects of specific deletion of PHGDH in lymphatic endothelia cells. Data related to Fig.4P-R; Fig.S15. The evaluation of different lactylated histones in CAFs; Fig.S16. The distance between CAFs and Tregs in human and mouse models. Data related to Figure 6; Fig.S17. SenCAFs-derived lactate activates transcription of CCL17 by enhancing histone lactylation in LECs; Fig.S18. The HDAC inhibitor chidamide selectively kills senCAFs in PDAC; Fig.S19. The HDAC inhibitor chidamide selectively kills senCAFs, increases the efficacy of pancreatic cancer standard of care and further suppresses LNM and distal metastasis in PDAC;Fig.S20. The HDAC inhibitor chidamide could sensitize PDAC to chemoimmunotherapy;Fig.S21. The tumor re-challenge assay for chidamide plus chemoimmunotherapy; Fig.S22. The effects of chidamide in Pdgfrα-cre-p16/cdkn1aΔ and WT mice;Fig.S23. The therapeutic effects of gemcitabine, nab-paclitaxel, chidamide and QL1706 in PDX models;Fig.S24. Schematic illustration for the project.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure1-24 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Fig.S1. Analysis of the number of positive LNs and the lymph node ratio (LNR, the ratio of positive to examined nodes) in PDAC patients; Fig.S2. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S3. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S4. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S5. Validation of SPiDER probe and the effects of dasatinib plus quercetin; Fig.S6. The gating strategy for senescent cells and the senescence levels in normal tissues, IPMN and PDAC; Fig.S7. The effects of specific deletion of p16 and p21 in CAFs; Fig.S8.The effects of conditional deletion of p16 and p21 in CAFs; Fig.S9. Clinical significance of senescent CAFs in PDAC; Fig.S10. The paracrine effects of malignant epithelial components on the induction of senescent CAFs; Fig.S11. The validation of senescent CAFs; Fig.S12. The glucose metabolism level in senescent CAFs; Fig.S13. The effects of LDHA inhibition in LNM; Fig.S14. The effects of specific deletion of PHGDH in lymphatic endothelia cells. Data related to Fig.4P-R; Fig.S15. The evaluation of different lactylated histones in CAFs; Fig.S16. The distance between CAFs and Tregs in human and mouse models. Data related to Figure 6; Fig.S17. SenCAFs-derived lactate activates transcription of CCL17 by enhancing histone lactylation in LECs; Fig.S18. The HDAC inhibitor chidamide selectively kills senCAFs in PDAC; Fig.S19. The HDAC inhibitor chidamide selectively kills senCAFs, increases the efficacy of pancreatic cancer standard of care and further suppresses LNM and distal metastasis in PDAC;Fig.S20. The HDAC inhibitor chidamide could sensitize PDAC to chemoimmunotherapy;Fig.S21. The tumor re-challenge assay for chidamide plus chemoimmunotherapy; Fig.S22. The effects of chidamide in Pdgfrα-cre-p16/cdkn1aΔ and WT mice;Fig.S23. The therapeutic effects of gemcitabine, nab-paclitaxel, chidamide and QL1706 in PDX models;Fig.S24. Schematic illustration for the project.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2-3 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 2 shows the patient characteristics in the proof-of-concept clinical trial; Supplementary Table 3 shows treatment-related adverse events in the proof-of-concept clinical trial.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2-3 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 2 shows the patient characteristics in the proof-of-concept clinical trial; Supplementary Table 3 shows treatment-related adverse events in the proof-of-concept clinical trial.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table1 shows the senescence genesets
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table1 shows the senescence genesets
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Detailed Supplementary Methods 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Detailed Supplementary Methods and Materials
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessDetailed Supplementary Methods 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Detailed Supplementary Methods and Materials
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 4 shows primers and probes used in experiments.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 4 shows primers and probes used in experiments.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF23
Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Lymph node (LN) metastasis (LNM) in early-stage pancreatic ductal adenocarcinoma (PDAC) predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. In this study, we demonstrated that senescent cancer-associated fibroblasts (senCAF) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ regulatory T cells from the draining LNs accumulated around lymphatic vessels, which established an immunosuppressive perilymphatic niche. High-throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression, and improved chemoimmunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti–PD-1/CTLA-4) in patients with metastatic PDAC and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemoimmunotherapy efficacy. Significance: Our findings have revealed a closed link between cellular senescence, metabolic reprograming, and spatial immunosuppressive niche and PDAC metastasis, offering the potential senolytic drugs to improve chemoimmunotherapy efficacy in patients with PDAC.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF23
Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Lymph node (LN) metastasis (LNM) in early-stage pancreatic ductal adenocarcinoma (PDAC) predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. In this study, we demonstrated that senescent cancer-associated fibroblasts (senCAF) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ regulatory T cells from the draining LNs accumulated around lymphatic vessels, which established an immunosuppressive perilymphatic niche. High-throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression, and improved chemoimmunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti–PD-1/CTLA-4) in patients with metastatic PDAC and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemoimmunotherapy efficacy. Significance: Our findings have revealed a closed link between cellular senescence, metabolic reprograming, and spatial immunosuppressive niche and PDAC metastasis, offering the potential senolytic drugs to improve chemoimmunotherapy efficacy in patients with PDAC.
- 6 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (2) , 207-212
Senescence as the Next Frontier in Cancer Research: Navigating the Rising Tide of Geriatric Oncology
Summary: The global demographic shift toward an aging population has positioned cancer as a preeminent challenge in public health, with the incidence of most malignancies increasing precipitously with advancing age. By targeting the bidirectional nexus of cancer and aging, we can pioneer precision interventions to improve outcomes for the growing geriatric oncology population.
- 6 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (2) , 207-212
Senescence as the Next Frontier in Cancer Research: Navigating the Rising Tide of Geriatric Oncology
Summary: The global demographic shift toward an aging population has positioned cancer as a preeminent challenge in public health, with the incidence of most malignancies increasing precipitously with advancing age. By targeting the bidirectional nexus of cancer and aging, we can pioneer precision interventions to improve outcomes for the growing geriatric oncology population.